首页> 美国卫生研究院文献>BioMed Research International >Skin Delivery of Kojic Acid-Loaded Nanotechnology-Based Drug Delivery Systems for the Treatment of Skin Aging
【2h】

Skin Delivery of Kojic Acid-Loaded Nanotechnology-Based Drug Delivery Systems for the Treatment of Skin Aging

机译:载有曲酸的基于纳米技术的药物递送系统的皮肤递送,用于治疗皮肤老化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aging process causes a number of changes in the skin, including oxidative stress and dyschromia. The kojic acid (KA) is iron chelator employed in treatment of skin aging, and inhibits tyrosinase, promotes depigmentation. Nanotechnology-based drug delivery systems, such as liquid crystalline systems (LCSs), can modulate drug permeation through the skin and improve the drug activity. This study is aimed at structurally developing and characterizing a kojic acid-loaded LCS, consists of water (W), cetostearyl isononanoate (oil—O) and PPG-5-CETETH-20 (surfactant-S) and evaluating its in vitro skin permeation and retention. Three regions of the diagram were selected for characterization: A (35% O, 50% S, 15% W), B (30% O, 50% S, 20% W) and C (20% O, 50% S, 30% W), to which 2% KA was added. The formulations were subjected to polarized light microscopy, which indicated the presence of a hexagonal mesophase. Texture and bioadhesion assay showed that formulation B is suitable for topical application. According to the results from the in vitro permeation and retention of KA, the formulations developed can modulate the permeation of KA in the skin. The in vitro cytotoxic assays showed that KA-unloaded LCS and KA-loaded LCS didn't present cytotoxicity. PPG-5-CETETH-20-based systems may be a promising platform for KA skin delivery.
机译:衰老过程引起皮肤的许多变化,包括氧化应激和色差。曲酸(KA)是用于治疗皮肤衰老的铁螯合剂,可抑制酪氨酸酶,促进色素沉着。基于纳米技术的药物输送系统,例如液晶系统(LCS),可以调节药物通过皮肤的渗透并改善药物活性。这项研究的目的是从结构上开发和表征载有曲酸的LCS,它由水(W),鲸蜡硬脂基异壬酸(油-O)和PPG-5-CETETH-20(表面活性剂S)组成,并评估其体外皮肤渗透性和保留。选择了图表的三个区域进行表征:A(35%O,50%S,15%W),B(30%O,50%S,20%W)和C(20%O,50%S, 30%W),其中添加了2%KA。对制剂进行偏振光显微镜检查,这表明存在六方中间相。质地和生物粘附测定表明制剂B适用于局部应用。根据KA的体外渗透和保留结果,开发的制剂可以调节KA在皮肤中的渗透。体外细胞毒性试验表明,未加载KA的LCS和未加载KA的LCS没有细胞毒性。基于PPG-5-CETETH-20的系统可能是用于KA皮肤递送的有前途的平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号